Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling

[1]  L. Liñán-Rico,et al.  Differential Activity of Voltage- and Ca2+-Dependent Potassium Channels in Leukemic T Cell Lines: Jurkat Cells Represent an Exceptional Case , 2018, Front. Physiol..

[2]  C. Lindsley,et al.  Classics in Chemical Neuroscience: Memantine. , 2017, ACS chemical neuroscience.

[3]  E. Venturini,et al.  Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo. , 2017, Cancer cell.

[4]  W. Linehan,et al.  Ionic immune suppression within the tumour microenvironment limits T cell effector function , 2016, Nature.

[5]  U. Bommhardt,et al.  Immunomodulation by memantine in therapy of Alzheimer's disease is mediated through inhibition of Kv1.3 channels and T cell responsiveness , 2016, Oncotarget.

[6]  M. Zoratti,et al.  Pharmacological targeting of ion channels for cancer therapy: In vivo evidences. , 2016, Biochimica et biophysica acta.

[7]  L. Leanza,et al.  Biophysical Characterization and Expression Analysis of Kv1.3 Potassium Channel in Primary Human Leukemic B Cells , 2015, Cellular Physiology and Biochemistry.

[8]  K. Michalak,et al.  Voltage-Gated Potassium Channels Kv1.3--Potentially New Molecular Target in Cancer Diagnostics and Therapy. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[9]  S. Feske,et al.  Ion channels in innate and adaptive immunity. , 2015, Annual review of immunology.

[10]  C. Baldus,et al.  Outlook on PI3K/AKT/mTOR inhibition in acute leukemia , 2015, Molecular and Cellular Therapies.

[11]  K. Brown,et al.  The phosphoinositide 3-kinase pathway and therapy resistance in cancer , 2015, F1000prime reports.

[12]  G. Ossenkoppele,et al.  How I treat the older patient with acute myeloid leukemia. , 2015, Blood.

[13]  U. Bommhardt,et al.  NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells , 2014, Cell Communication and Signaling.

[14]  J. Bradner,et al.  Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia. , 2014, Cancer research.

[15]  A. Ferrando,et al.  N-Me, a long range oncogenic enhancer in T-cell acute lymphoblastic leukemia , 2014, Nature medicine.

[16]  L. Zender,et al.  Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles , 2014, Nature.

[17]  R. Greil,et al.  Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade , 2014, Leukemia.

[18]  B. Nadel,et al.  Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL) , 2014, Oncotarget.

[19]  Christine Beeton,et al.  Ion channels and anti-cancer immunity , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  R. Sprengel,et al.  Immunosuppression by N-Methyl-d-Aspartate Receptor Antagonists Is Mediated through Inhibition of Kv1.3 and KCa3.1 Channels in T Cells , 2013, Molecular and Cellular Biology.

[21]  C. Plass,et al.  Epo-induced erythroid maturation is dependent on Plcγ1 signaling , 2014, Cell Death and Differentiation.

[22]  M. Zoratti,et al.  Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia , 2013, Leukemia.

[23]  P. Chevallier,et al.  A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse , 2013, Leukemia.

[24]  C Shepherd,et al.  PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response , 2012, Leukemia.

[25]  F. Peyrade,et al.  Treatment decisions for elderly patients with haematological malignancies: a dilemma. , 2012, The Lancet. Oncology.

[26]  Hui-Kuan Lin,et al.  Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. , 2012, Cancer research.

[27]  K. Chandy,et al.  Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells , 2012, EMBO molecular medicine.

[28]  L. Conforti.  The ion channel network in T lymphocytes, a target for immunotherapy. , 2012, Clinical immunology.

[29]  A. Becchetti,et al.  Targeting ion channels in leukemias: a new challenge for treatment. , 2012, Current medicinal chemistry.

[30]  E. Condom,et al.  Targeting the voltage-dependent K(+) channels Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention. , 2012, Current medicinal chemistry.

[31]  K. Flatten,et al.  Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. , 2012, Blood.

[32]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[33]  Heike Wulff,et al.  Voltage-gated potassium channels as therapeutic targets , 2009, Nature Reviews Drug Discovery.

[34]  M. Carroll,et al.  A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia , 2009, Clinical Cancer Research.

[35]  K. Chandy,et al.  The functional network of ion channels in T lymphocytes , 2009, Immunological reviews.

[36]  L. Chin,et al.  High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. , 2009, Blood.

[37]  T. Ikezoe,et al.  Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells , 2009, Apoptosis.

[38]  J. McCubrey,et al.  Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. , 2009, Cancer research.

[39]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[40]  F. Lang,et al.  Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes , 2008, Proceedings of the National Academy of Sciences.

[41]  Stephen L. Abrams,et al.  Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy , 2008, Leukemia.

[42]  C. Parsons,et al.  Pharmacodynamics of Memantine: An Update , 2008, Current neuropharmacology.

[43]  Ingo Schmitz,et al.  Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membrane depolarization. , 2006, Molecular biology of the cell.

[44]  D. Teachey,et al.  The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. , 2006, Blood.

[45]  M. Tomasson,et al.  c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. , 2005, Blood.

[46]  F. Lang,et al.  A Novel Potassium Channel in Lymphocyte Mitochondria* , 2005, Journal of Biological Chemistry.

[47]  Steven M Kornblau,et al.  Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. , 2004, Blood.

[48]  J. Barata,et al.  Activation of PI3K Is Indispensable for Interleukin 7–mediated Viability, Proliferation, Glucose Use, and Growth of T Cell Acute Lymphoblastic Leukemia Cells , 2004, The Journal of experimental medicine.

[49]  J. Trapani,et al.  A new quantitative assay for cytochrome c release in apoptotic cells , 2003, Cell Death and Differentiation.

[50]  G. Laurent,et al.  Daunorubicin- and Ara-C-induced interphasic apoptosis of human type II leukemia cells is caspase-8-independent. , 2002, Biochimica et biophysica acta.

[51]  M. Brizzi,et al.  HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors , 2002, Leukemia.

[52]  R. Tallarida.  The interaction index: a measure of drug synergism , 2002, Pain.

[53]  D. Seol,et al.  Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. , 2001, Cancer research.

[54]  Mark J. Miller,et al.  Up-regulation of the IKCa1 Potassium Channel during T-cell Activation , 2000, The Journal of Biological Chemistry.

[55]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[56]  J. Troppmair,et al.  Regulation of c-myc expression by Ras/Raf signalling , 1998, Oncogene.

[57]  A. L. Goldin,et al.  Expression and chromosomal localization of a lymphocyte K+ channel gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  T. Wise-Draper,et al.  Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer. , 2017, Cancer research.

[59]  P. O’Reilly,et al.  Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. , 2014, Current pharmaceutical design.

[60]  J. McCubrey,et al.  PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. , 2012, Advances in biological regulation.

[61]  Stephen L. Abrams,et al.  Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy , 2011, Leukemia.